Latest Imatinib Stories
EAST HANOVER, N.J., June 1, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") will showcase data from 140 abstracts on its current oncology products and investigational agents at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Scientists at The Feinstein Institute for Medical Research discovered a molecule called c-Abl that has a known role in leukemia also has a hand in Alzheimerâ€™s disease. Manhasset, NY (PRWEB) May 26, 2011 After decades of studying the pathological process that wipes out large volumes of memory, scientists at The Feinstein Institute for Medical Research discovered a molecule called c-Abl that has a known role in leukemia also has a hand in Alzheimerâ€™s disease.
WAYNE, N.J., May 10, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that its investigational compound regorafenib (BAY 73-4506) has been granted Fast Track designation by the U.S.
While the median age at diagnosis for chronic myeloid leukemia (CML) is over 60 years old and incidence increases dramatically with age,limited data are available about the long-term outcome for older patients treated with imatinib, the standard first-line therapy used to treat CML.
Patients taking imatinib (Gleevec) for CML, or chronic myelogenous leukemia, and in remission after two years of treatment, have a mortality rate similar to that of the general population according to a study published online [date] in the Journal of the National Cancer Institute.
Researchers at Oregon Health & Science University Doernbecher Children's Hospital have defined the cell of origin for a kind of cancer called sarcoma.
Scientists now know that some cancer cells spread, or metastasize, throughout the body the old-fashioned way -- by using their feet.
Chronic myeloid leukemia (CML) was transformed from a fatal disease to a chronic condition by the development of a drug known as imatinib, which targets the protein that drives this disease (BCR-ABL).
A new drug appears to help chronic myeloid leukemia patients who are out of treatment options after first- and second-line drugs have failed them or because their cancer cells have a mutation that makes them resistant from the start.
Over the past decade, significant advances have been made in the treatment of leukemia through the ongoing development of gene-based targeted therapies.
- A poem in which the author retracts something said in an earlier poem.